礼来将收购Orna Therapeutics以推进细胞疗法的发展-动脉网

Lilly to acquire Orna Therapeutics to advance cell therapies

礼来等信源发布 2026-02-09 20:04



可切换为仅中文







Orna's in vivo CAR-T pipeline includes potential best-in-class programs to reset the immune system and address B cell-driven autoimmune diseases

奥尔纳的体内CAR-T管线包括潜在的同类最佳项目，可重置免疫系统并解决B细胞驱动的自身免疫疾病。

Acquisition provides a broad platform for long-term innovation in genetic medicine and in vivo cell engineering

收购为基因医学和体内细胞工程的长期创新提供了一个广阔的平台

INDIANAPOLIS

印第安纳波利斯

and

和

WATERTOWN, Mass.

马萨诸塞州沃特敦

，

Feb. 9, 2026

2026年2月9日

/PRNewswire/ --

Eli Lilly and Company

礼来公司

(NYSE: LLY) and

(NYSE: LLY) 和

Orna Therapeutics, Inc.

奥尔纳治疗公司

, a biotechnology company dedicated to engineering immune cells

，一家致力于改造免疫细胞的生物技术公司

in vivo

体内

, today announced entry into a definitive agreement for Lilly to acquire Orna.

今天宣布达成一项最终协议，礼来公司将收购奥尔纳。

Orna is advancing a new class of therapeutics utilizing engineered circular RNA paired with novel lipid nanoparticles to allow the patient's own body to generate cell therapies that can treat underlying disease. Orna's lead program is ORN-252, a clinical trial-ready, CD19 targeting

奥尔纳正在推进一类新的治疗方法，利用工程化的环状RNA与新型脂质纳米颗粒相结合，使患者自身身体能够生成可治疗潜在疾病的细胞疗法。奥尔纳的主导项目是ORN-252，这是一种已准备好进行临床试验、靶向CD19的产品。

in vivo

体内

Chimeric Antigen Receptor T-cell (CAR-T) therapy designed to treat B cell-driven autoimmune diseases. Experiments to date suggest that Orna's circular RNA platform may deliver more durable expression of therapeutic proteins and therefore unlock treatments that are not feasible with current RNA or cell therapy platforms..

嵌合抗原受体T细胞（CAR-T）疗法旨在治疗B细胞驱动的自身免疫疾病。迄今为止的实验表明，Orna的环状RNA平台可能会实现更持久的治疗蛋白表达，从而解锁当前RNA或细胞治疗平台无法实现的治疗方法。

'Early autologous CAR-T studies have shown the promise of cell therapy for patients with autoimmune diseases, but the complexity, cost, and logistics of

“早期的自体CAR-T研究已经展示了细胞疗法对自身免疫疾病患者的潜力，但其复杂性、成本和物流方面的问题仍然存在，

ex vivo

离体

approaches make it challenging to deliver these breakthroughs to the broader population of patients who need them,' said Francisco Ramírez-Valle M.D., Ph.D., Senior Vice President, Head of

方法使得将这些突破性成果带给更广泛的患者群体变得具有挑战性，”弗朗西斯科·拉米雷斯-瓦勒医学博士、哲学博士、高级副总裁、负责人表示，

Immunology Research

免疫学研究

and

和

Early Clinical Development

早期临床开发

. 'We look forward to working with Orna colleagues to potentially unlock an entirely new class of genetic medicines and cell therapies for patients who today have limited or no treatment options.'

“我们期待与Orna的同事们合作，为那些目前治疗选择有限或无治疗选择的患者，开发出一类全新的基因药物和细胞疗法。”

'At Orna, we believe our circular RNA technology paired with our best-in-class LNP delivery platform have the potential to unlock

“在Orna，我们相信我们的环状RNA技术与我们一流的LNP递送平台相结合，有潜力释放

in vivo

体内

CAR-T therapies for patients across a wide range of B cell-driven autoimmune diseases. We are excited to join forces with Lilly, an industry leader in the development of patient-centric therapeutics to realize the full potential of these technologies,' said

针对广泛的B细胞驱动的自身免疫疾病患者，我们很高兴与礼来公司携手合作，礼来是开发以患者为中心的治疗药物的行业领导者，共同实现这些技术的全部潜力。

Joe Bolen

乔·博伦

, Ph.D., Chief Executive Officer of

，博士，首席执行官

Orna Therapeutics

奥尔纳治疗公司

。'

Under the terms of the agreement, Lilly will acquire Orna, and Orna shareholders could receive up to

根据协议条款，礼来公司将收购奥尔纳公司，奥尔纳公司的股东们最多可获得

$2.4 billion

24亿美元

in cash, inclusive of an upfront payment and subsequent payments upon achievement of certain clinical development milestones.

现金支付，包括首付款以及在达成某些临床开发里程碑后的后续付款。

Lilly will determine the accounting treatment of this transaction in accordance with Generally Accepted Accounting Principles (GAAP) upon closing. This transaction will thereafter be reflected in Lilly's financial results and financial guidance.

礼来公司将根据公认会计原则 (GAAP) 在交易结束时确定该交易的会计处理方法。此后，该交易将反映在礼来的财务结果和财务指导中。

Paul, Weiss, Rifkind, Wharton & Garrison LLP

保罗·韦斯·里夫金德·沃顿与加里森律师事务所

is acting as legal counsel to Lilly. Lazard is acting as financial advisor to Orna.

正在担任礼来的法律顾问。拉扎德正担任Orna的财务顾问。

Goodwin Procter LLP

古德温·普罗克特律师事务所

is acting as legal counsel to Orna.

担任奥尔娜的法律顾问。

About Lilly

关于礼来

Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases.

礼来是一家医药公司，将科学转化为治疗手段，以改善世界各地人们的生活。近150年来，我们一直致力于开创改变生命的发现，如今我们的药物已帮助全球数千万人。通过利用生物技术、化学和基因医学的力量，我们的科学家正在加速推进新的发现，以解决一些全球最重要的健康挑战：重新定义糖尿病护理；治疗肥胖症并遏制其最具破坏性的长期影响；推动对抗阿尔茨海默病的斗争；为一些最严重的免疫系统疾病提供解决方案；并将最难治疗的癌症转化为可控制的疾病。

With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. F-LLY.

每迈向更健康的世界一步，我们都受到一个目标的激励：让数百万人的生活更美好。这包括开展反映世界多样性的创新临床试验，并努力确保我们的药物可及且负担得起。F-LLY。

About

关于

Orna Therapeutics

奥尔纳治疗公司

Orna Therapeutics

奥尔娜治疗公司

is dedicated to designing and delivering a new class of fully engineered circular RNA (oRNA

致力于设计和交付一类全新的完全工程化的环状RNA（oRNA）

) therapeutics to unlock the potential of RNA medicine to treat diseases anywhere in the body. Orna's oRNA transcripts have advantages over traditional mRNA approaches, including simplified production, improved formulation into lipid nanoparticles, and superior protein expression. Its industry-leading LNP-based delivery systems and comprehensive editing programs position Orna to advance novel RNA medicines with vast potential to transform patient care. .

）疗法，以释放RNA药物在治疗全身任何部位疾病方面的潜力。Orna的oRNA转录本相比传统的mRNA方法具有多项优势，包括简化的生产流程、改进的脂质纳米颗粒制剂以及更优越的蛋白表达。其行业领先的基于LNP的递送系统和全面的编辑项目使Orna能够推进具有巨大潜力的新型RNA药物，从而彻底改变患者护理。

Cautionary Statement Regarding Forward-Looking Statements

关于前瞻性声明的警示声明

This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about the benefits of Lilly's acquisition of Orna and Orna's Circular RNA therapeutics and LNP delivery platform, including its CAR-T program, and reflects Lilly's current beliefs and expectations.

本新闻稿包含关于礼来收购奥尔纳及奥尔纳的环状RNA治疗药物和LNP递送平台（包括其CAR-T项目）的利益相关的前瞻性陈述（该术语定义见1995年私人证券诉讼改革法案），并反映了礼来的当前信念和期望。

However, as with any such undertaking, there are substantial risks and uncertainties in implementing the acquisition and in the process of drug research, development, and commercialization. Among other things, there can be no guarantee that Lilly will realize the expected benefits of the acquisition, that the acquisition will achieve the results discussed in this release or that the acquisition will yield commercially successful products.

然而，与任何此类行动一样，在实施收购以及药物研发、开发和商业化过程中存在重大风险和不确定性。其中，不能保证礼来公司能够实现收购的预期效益，不能保证收购将达成此公告中讨论的结果，也不能保证收购将产生商业上成功的产品。

For further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release..

有关这些可能导致实际结果与礼来公司预期不同的风险和其他不确定性的进一步讨论，请参阅礼来公司向美国证券交易委员会提交的Form 10-K和Form 10-Q报告。除非法律要求，礼来公司没有义务更新前瞻性声明以反映本发布日期之后的事件。

No Offer or Solicitation

无提供或招揽

This communication is for information purposes only and is not intended to and does not constitute, or form part of, an offer, invitation or the solicitation of an offer or invitation to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of any securities, or the solicitation of any vote or approval in any jurisdiction, pursuant to the proposed acquisition or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law..

本通讯仅作信息用途，无意且不构成、或成为任何要约、邀请或要约或邀请的一部分，以购买、收购、认购、出售或处置任何证券，或在任何司法管辖区征求任何投票或批准，无论是根据拟议的收购还是其他情况；也不得在违反适用法律的情况下，在任何司法管辖区进行证券的销售、发行或转让。

Refer to:

参考：

Ashley Hennessey

阿什利·亨尼西

;

；

gentry_ashley_jo@lilly.com

; 317-416-4363 (Media)

；317-416-4363（媒体）

Michael Czapar;

迈克尔·查帕尔；